Abstract
Human dermal sleeping nociceptors display ongoing activity in neuropathic pain, affecting 10% of the population. Despite advances in rodents, a molecular marker for these mechano-insensitive C-fibers (CMis) in human skin remains elusive, preventing targeted therapy. In this translational Patch-seq study, we combine single-cell transcriptomics following electrophysiological characterization with single-nucleus and spatial transcriptomics from pigs and humans. We functionally identified CMis in pig sensory neurons with patch-clamp using adapted protocols from human microneurography. We identified oncostatin-M-receptor (OSMR) and somatostatin (SST) as marker genes for CMis. Following dermal injection in healthy human volunteers, oncostatin-M, the ligand of OSMR, exclusively modulates CMis. We identified the entire molecular architecture of human dermal sleeping nociceptors, providing new therapeutic targets and the basis for a mechanistic understanding of neuropathic pain.
One Sentence Summary We identify the molecular architecture and specifically OSMR and SST as molecular markers for human dermal sleeping nociceptors, key players in the generation of neuropathic pain.
Short version In this Patch-seq study, we identify OSMR and SST as molecular markers for human dermal sleeping nociceptors, key players in the generation of neuropathic pain.
Competing Interest Statement
AL and TJP receive counselling fees from and had research contracts with Gruenenthal. WR received counseling fees from Gruenenthal and has a research contract from Pfizer. Parts of the data in the manuscript (Costs for consumables, services and salary for sequencing Visium spatial transcriptomics and parts of the PatchSeq experiments) were generated within a research contract with Gruenenthal. BN has a counselling contract with Vertex. All other authors declare that they have no competing interests.
